{"name":"Elevation Oncology","slug":"elevation-oncology","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQMlBBVHpoQnR3T3JaR3Q2ZDVZODVna19yUHk4WUNyMks2YTNJdG1kWnlFNUZHZHg4WkttQnVBQVR1WnVFTDh0VDBMRVI4SmN0RG4yd3JIa05wNUd3NTRKOUZlUHpRdmJSeUhHeE9mZHhUTVBFY0lpa3NyWGZnXzRsLWl2UUhlOUxPZUZRMkhhc254bkIxV3NORVQxMlR0dw?oc=5","date":"2025-07-02","type":"pipeline","source":"Fierce Biotech","summary":"Why 'emboldened' activist investors are taking the fight to biotechs - Fierce Biotech","headline":"Why 'emboldened' activist investors are taking the fight to biotechs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQeVdEV2g2cjJKdmNsakVINkM2NmZOU2JDX3JHbV9SdS1NYnJGR0NqX2M0YUI1eTJwekJMZWt1WE5Oclh2LUZaN3FmT1VVRmdWQlFCZV8wUTgwTFlTU19QZnM0cUp5YkdQMXZaNGlaV2RYNmNPeU5hd3J6OGR5ODg0bW5zcm1FR0x1cW15cFBXOFU3TVYwckx1eENSTFFvTE0?oc=5","date":"2025-06-10","type":"deal","source":"The Pharma Letter","summary":"Elevation Oncology agrees to be acquired by Concentra - The Pharma Letter","headline":"Elevation Oncology agrees to be acquired by Concentra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNZUo0U2dNV3ZXajJZbzgwY1hYYk1WZlI4Y1E5V2YzR3o3SVZObDhmZVlmSGRXWDRJTzcxRnZzanZzZTBtVGlkWFJvSlo2RDA0c1RqUW5yY255bWtIU3lCVHJ1R054TUdscXVwT2dzcTA2VHhIV2ptUUhSaEduQlpKQ0NUMWNhVVpqbnBlcVMzNUNWcWJGZHlPVDM1Yk02MU1GX2c?oc=5","date":"2025-06-09","type":"deal","source":"BioPharma Dive","summary":"Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’ - BioPharma Dive","headline":"Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxOTkxSWFlnTUcyU1RfWnc1SUl3S2hNdWdWR1loVkNIRlNiczJUVjU4MnZpZkdha3o4WUhZbUhVYmUySGx2RzZ2UG5CdHFaZFZpa3lrV1FkeXFLbGlrbzBoRVVnY2Y3NzZfa1oxbC0ybXktWFZNVEJQYVktdkhhME5NZzFpbEZtWDhrTjlzWmxFUkRvemIzVDdIVTRheFByaDM2SkYyeFN0OGprZWlhNDZrclFsck5HTDV3cC1mV1ROWHgzT3hUOHdUNkpUdkdCSUQxdndicV84dThTaDRmWXZ2YUlqR3NrTVdwQ01nbVduanBKTElxTHU5ZURYVjBRTlFpbkYwNnctYzRaMW1DaFV2ZU8zSU1ZcTEtcXB5eFl3?oc=5","date":"2025-06-09","type":"deal","source":"prnewswire.com","summary":"Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right - prnewswire.com","headline":"Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Cont","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOSzM3WnRaMEN3QXpUbXRKbjJTMzNTV1d1SEhlUHpRTG1kV1VXeWs4aWhQU3dkVVlhYmRlbzVNZnhjbW03YUVxMEg1dy1ZS3hNakFZdzlRbDk0N0c5YmduTG44N1ZVVkdTQkxXbEI5WDVaV2F1Q1pGLXp1Y3JEYXRBYWk5NTJxM1Jid05GLWthbGdiUnNONTBLZFNPRUNUM2NWTkxYWVZ3?oc=5","date":"2025-04-17","type":"regulatory","source":"Fierce Biotech","summary":"Elevation faces activist investor demands to wind down - Fierce Biotech","headline":"Elevation faces activist investor demands to wind down","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQdTROTE9UbndqTWZ2ZnYxand0RGJuejYyTEZ5eXgwYi1nVWhRbnF2TEYzSUxSM2lUUG5FQlkwM2pwZkI4b2d2U1BFX3U5TnJHQWkyb05tSG9ZUUMwQjJNWnVqY1ZhSWRKYVEwWllnNW5JczFVd0dWTHpFVFhfUVdnNXBZbXZGVG5HTmc?oc=5","date":"2025-03-21","type":"pipeline","source":"Yahoo Finance","summary":"Elevation Oncology Plunges 42% on Ending Development of Lead Drug - Yahoo Finance","headline":"Elevation Oncology Plunges 42% on Ending Development of Lead Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNUUlPM2Q0N0tFTVpMVVBxdG9FYnc1enMxR0FLQnE1V0Y5c2hYODM1aEJ2RW1Kc3o2ZW53M0trbHNydVExVGFsZUh0X0VWb0pOUVJlYkU0dDVMcm96VGJFMDVnbk02dXZSR0l0UzBKRllUMllsblQwNE5VNFl6SVRLVHBpdUU?oc=5","date":"2025-03-20","type":"trial","source":"Oncology Pipeline","summary":"Elevation goes down on Claudin disaster | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Elevation goes down on Claudin disaster | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE8tWVRTakgtUUdyZ2R6ZUM1UldxY3RxTHVCMmMyRjhYWlJmNzRHd0VlWUVRalVSOXJIWFRQQmNveUV3QnpTT20zeXdCcVF1Sm44QmFV?oc=5","date":"2025-03-20","type":"pipeline","source":"FirstWord Pharma","summary":"Shares drop as Elevation axes Claudin 18.2 ADC, slashes jobs - FirstWord Pharma","headline":"Shares drop as Elevation axes Claudin 18.2 ADC, slashes jobs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNa2dsd1ozOHVoUlpRWnRoS09WckNIWmZCb1kyRDhVaE1mYkc3UkRYZFJkbXNUaTdkS05Eb0hhZGs5OXUtS3lROV9nVUEtRGpaS1lSa0xmSm1CYWpPTERuN3YtcmdnUmtqUGRmWVA5bXdzaElxbzdyTlhvVTVTYUlLZHJsVGpHMTBEQ21zSHlIc0llTVJwYkFKTFV4X3NPVTM3a05CX2EtMzJMcHdicjk0RlhmSmI1UzZCTmgzQ09oQm9HUXpfMDFrci1mcnk2SWpId2NzSUo3NmItSjZrZWR5aGo0VE43blFnUElWenZBc2Z5SHgtN0V0Vw?oc=5","date":"2025-03-20","type":"pipeline","source":"prnewswire.com","summary":"Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options - prnewswire.com","headline":"Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNMmZBTGo1Qm8yNDRWSGNjN3lmbGxaNHNKdjVwZ2kxZnBnVkdiM2tYYTMzVVkzeVZucUR0TWVyakNibHRINzhXYmRxTkgtNkQzRUtMVUE1LUQ0XzR6MF82Y01aODdNdGV0cEtpUjV3SGhySk9WTFl5VHBLbkJDUVN6ekgtcmdJVF93QWtjQUMxUENEUnZpOFhLY3o5aEg1WjBLNGhGMWo1V0JjTk5ZM3BLRTZFelhDR1dUd1JpelZUNk1UVGZpZTVVZ1ZSYlBhYlpNb0J4dG8tNW12YlA4eHNnSlB0ZTNGa2VJSEFVS2IybzBQWmFhQjBqLWRMc0NydEJyZUZMUDY0Z0I3QQ?oc=5","date":"2025-03-06","type":"earnings","source":"prnewswire.com","summary":"Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements - prnewswire.com","headline":"Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievemen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOWEVHNWd5bGJuWGQwR1I1ajFONUZTRG10ank2SDVUdE9zRW9GUXhOaFJJRFBMVDVxUWVXcVpYRDh2RUlrdVBqX3EzTXFVcjRqMzhwR2hkWmVnQ3g4RWRpdzIzekNiVEk0dFB5NGJtUDZaOHVzSlQ4MzVqMk1TbHQ4aDZETl96dWdpTUJxbHVWc05rOFpuWUQw?oc=5","date":"2024-08-06","type":"trial","source":"Oncology Pipeline","summary":"Claudin18.2 expression clouds Elevation's big reveal | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Claudin18.2 expression clouds Elevation's big reveal | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxPc1dWZTVqbUUwMnVJMEstTjVWZHc3RGhiamRLaEtzVTR1aV9rR0pheTRWeXBQM1ozUk1sd1VzOFR0U0RfNVNHZWxoZl9falMyUkt1YWs0SXBKQV9TTVg4OVF1aldIVmY2X0hnM09fWGNDMHRFX21EVlRtdktYU3VKTWVnVjhlZ1pjQ3dzbXlJTHZZUWJEc0tDa19VX3pHUzNyYnJvUTNoSjQ4bS1CTV9wM2h3WTZaWlZVMnZHVW14MHY3MnoyNFVmVk9SZXJaMUpPNXhlR2ZqUHdma1BvMTVGcVFzMm03ZlV5NGJXMmxzbFAtU3d1NDlJUEEzQ1l5dDh5MFJVM1FRcHBkaExTbW1NNGEtUEVWbE5XcnA2MEJpYy1lSDFJTmpMckRJOU9yUXlORkIzNnQzWTVfN0QzemtjWVRsYzc3VERBS3JrVw?oc=5","date":"2022-07-28","type":"pipeline","source":"prnewswire.com","summary":"Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group - prnewswire.com","headline":"Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}